Ardaman Shergill to Biomarkers, Tumor
This is a "connection" page, showing publications Ardaman Shergill has written about Biomarkers, Tumor.
Connection Strength
1.182
-
Association of Activating GNAS Mutations and Outcomes with Chemotherapy in Metastatic Appendiceal Adenocarcinoma. Ann Surg Oncol. 2026 Apr; 33(4):3453-3461.
Score: 0.486
-
Utility of Circulating Tumor DNA Assessment in Characterizing Recurrence Sites after Optimal Resection for Metastatic Colorectal Cancer. J Am Coll Surg. 2024 06 01; 238(6):1013-1020.
Score: 0.423
-
Consensus Molecular Subtypes Inform HIPEC Agent Selection in Colorectal Cancer Peritoneal Metastases. Ann Surg Oncol. 2026 Jul; 33(7):6140-6145.
Score: 0.121
-
Investigating the Use of Circulating Tumor DNA in Early-Stage Colon Cancer. Oncology (Williston Park). 2022 10 07; 36(10):620-626.
Score: 0.096
-
Predictive Role of Circulating Tumor DNA in Stage III Colon Cancer Treated With Celecoxib: A Post Hoc Analysis of the CALGB (Alliance)/SWOG 80702 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2026 02 01; 12(2):149-158.
Score: 0.030
-
Brief Report: Discordance Between Liquid and Tissue Biopsy-Based Next-Generation Sequencing in Lung Adenocarcinoma at Disease Progression. Clin Lung Cancer. 2023 05; 24(3):e117-e121.
Score: 0.025